1/13/2024 0 Comments Netspot radiopharmaceuticalThere might be a small risk of peptides or antibodies causing people to have harsh immune system reactions (immunogenic), particularly after multiple injections, but generally the doses are extremely small and illicit minimal reactions. The radiopharmaceutical is usually prepared fresh (radioactive half-life prevents long-term storage), and the drug molecule is administered to the patient in a miniscule dose that is often referred to as “sub-pharmacological”, meaning the quantity of injected chemical is too low to elicit either positive or negative biological effects ( Figure 2). Cartoon illustration of a bifunctional chelate (BFC) based radiopharmaceutical agent, showing the BFC reacting with a biological targeting group such as a peptide or antibody. As drugs are often targeted very precisely to specific biological components such as cell-bound receptors, enzymes, ion-channels, transporter proteins, or certain physiochemical conditions (e.g., pH, oxygen levels), the attached radionuclide is simply a passenger that is secured to the drug and follows it to its biological target.įigure 1. 2 Thus, the drug portion acts as the delivery agent to provide site-specific delivery of the radionuclide, which is typically attached through chelation by a chelator ( Figure 1). 1 The goal for most radiopharmaceuticals is to achieve selective uptake and accumulation of radioactive elements in certain tissues (e.g., tumours, brain tissues, severe treatment resistant infections), which then enables minimally-invasive nuclear imaging or radionuclide therapy of the biological target. Radiopharmaceuticals can be created from scratch as entirely novel drug products, but they are often modified from existing and previously validated drugs, peptides, proteins, antibodies, nanoparticles, or many other exotic molecular scaffolds. I -, F 1-) or radioactive metal ions (radiometal, e.g. Radiopharmaceuticals are radioactive drugs which gain their radioactive properties by the secure chemical attachment of radioactive halogens (e.g. These radioactive “smart drugs” have the potential to become the new clinical standard for characterizing and treating diseases such as cancer, but they currently have several limitations that the Price Group aims to address (described below). These radioactive drugs have applications in both human and animal health, and in collaboration with the Royal University Hospital and the Western College of Veterinary Medicine at the U of S, they could have a direct impact on the health of animals and the Canadian population. Once injected, these radioactive “smart drugs” can selectively seek out cancerous cells or other diseased tissue in the body by binding selectively to diseased cells that present specific receptors or biological processes. These are radiopharmaceutical “smart drugs” that harness diagnostic and therapeutic radioactive metals. Peptide- and antibody-based radiopharmaceuticals prepared with radioactive metal ions are the focus of the Group. By creating next-generation radiopharmaceutical drugs, we are seeking to improve early detection and treatment of a variety of cancers and other diseases using molecular imaging techniques such as positron emission tomography (PET) imaging and treatment with targeted radionuclide therapy. The overarching goals of the Price Research Group are to improve the chemical properties of radiopharmaceutical drugs in a modular and widely-applicable way. Elaheh Khozeimeh Sarbisheh (left, currently at TRIUMF), Dr. We strive to find innovative solutions to real-world problems using fundamental chemical principles, including the creation of new radiopharmaceuticals and new chemical tools/reagents. We also actively research in the fields of radiochemistry, molecular imaging, and radionuclide therapy. To achieve this, the Price group performs multi-/inter-disciplinary research with a primary focus in chemical synthesis and subdisciplines including organic, inorganic, bioconjugate, computational modeling, and peptide chemistry. We are focused on using chemistry and radiochemistry to solve real-world problems in diagnosing and treating a variety of diseases, such as cancer. students, postdoctoral fellows, and research associates. Group members include a diverse mixture of members including undergraduates, M.Sc. The Price Research Group operates out of the University of Saskatchewan (USask) Chemistry Department. Creating new chemical tools for the construction of next-generation molecular imaging and radionuclide therapy drugsĭepartment of Chemistry, University of Saskatchewan, Saskatoon, Canada
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |